Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 519

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 519
---
 assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company’s auditor since 2022.

Whippany, New Jersey 
 May 13, 2024

<div align='center'>F-70</div>

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC BALANCE SHEETS
(in thousands)

| ​                                       
 ​                                       
 ASSETS                                  
 Current assets:                         | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | December 31, 
 2023         
 ​            
 ​            | ​ 
 ​ |       ​ 
       ​ | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | 2022 
 ​    
 ​    | ​ 
 ​ |       ​ 
       ​ | ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:----------------------------------------|:--|:--|:-------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Cash                                    | ​ | ​ | ​            | $ |     434 | ​ | ​ | ​ | ​    | $ |   5,048 | ​ | ​ |
| Loan receivable                         | ​ | ​ | ​            | ​ |     819 | ​ | ​ | ​ | ​    | ​ |       — | ​ | ​ |
| Advances for research and development   | ​ | ​ | ​            | ​ |       — | ​ | ​ | ​ | ​    | ​